Qiang M. Liu

74 Zhongshan 2nd Rd
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 165 publications

NFYA-Mediated TTK Up-Regulation Drives Fast Cell Cycle Progression and Its Inhibition Leads to Mitotic Catastrophe in Triple Negative Breast Cancer.

NFYA-Mediated TTK Up-Regulation Drives Fast Cell Cycle Progression and Its Inhibition Leads to Mitotic Catastrophe in Triple Negative Breast Cancer.

Journal: Cancers

Published: March 27, 2026

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Journal: BMJ (Clinical research ed.)

Published: March 16, 2026

Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.

Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.

Journal: Breast (Edinburgh, Scotland)

Published: February 06, 2026

A Tumor-Agnostic, Topology-Informed Scoring Framework for Drug Repurposing: Application to CDK4/6 Inhibitor Resistance in HR+ Breast Cancer.

A Tumor-Agnostic, Topology-Informed Scoring Framework for Drug Repurposing: Application to CDK4/6 Inhibitor Resistance in HR+ Breast Cancer.

Journal: Biomedicines

Published: January 23, 2026

Introduction and impact of the young breast cancer in China consensus.

Introduction and impact of the young breast cancer in China consensus.

Journal: Cancer biology & medicine

Published: December 19, 2025

Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil.

Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil.

Journal: Cell death & disease

Published: December 12, 2025

3D-printed cell-free bioactive scaffolds from methacrylated hyaluronic acid and silk fibroin incorporating platelet-rich plasma for adipose tissue regeneration.

3D-printed cell-free bioactive scaffolds from methacrylated hyaluronic acid and silk fibroin incorporating platelet-rich plasma for adipose tissue regeneration.

Journal: International journal of biological macromolecules

Published: December 03, 2025

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.

Journal: The oncologist

Published: October 01, 2025

Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.

Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.

Journal: BMJ (Clinical research ed.)

Published: September 11, 2025

Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis.

Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis.

Journal: The Journal of clinical investigation

Published: August 21, 2025

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study.

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study.

Journal: EClinicalMedicine

Published: July 30, 2025

Validation of Madecassoside Synergy Significantly Enhanced Cryptotanshinone's Therapeutic Efficacy Against Acne Vulgaris.

Validation of Madecassoside Synergy Significantly Enhanced Cryptotanshinone's Therapeutic Efficacy Against Acne Vulgaris.

Journal: Bioengineering (Basel, Switzerland)

Published: July 22, 2025

Showing 1-12 of 165

Last Updated: 09/26/2026